JAYPIRCA - (50MG, 100MG ; Tablet)

Generic Name	PIRTOBRUTINIB	**Innovator**	LOXO ONCOL
Dosage	50MG, 100MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	JAYPIRCA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inh bitor.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.